← Leaderboards
Richard J Samulski
Univ Of North Carolina Chapel Hill
$19,583,832
Attributed
$25,200,257
Total exposure
30
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$60,019,706 · 34
By mechanism
P01$34,947,291 · 13
R01$13,555,152 · 10
U54$8,974,815 · 3
R21$746,471 · 2
P60$707,687 · 1
P50$535,551 · 1
Top collaborators
- Chengwen Li20 shared
- Matthew Louis Hirsch8 shared
- Kyson Xiaohuai Chou2 shared
- Roland Michael Tisch2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Chengwen Li$10,504,911
- Joshua Greiger$1,603,384
- Elizabeth Pempe Chappell$49,249
- Juliane Nguyen$9,738,301
- Jessica Lea Hoffman$578,291
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyAdeno-Associated Viral VectorCapsidVectorBaseClinical TrialsSerotypingMutantIn VitroIn VivoEngineeringDependovirusTissuesAnimal ModelDesignTransfection /Expression VectorMediatingProteinsNeutralizing AntibodyGene DeliveryCellsGenesVirionDose
Grant awards (128)
Development of AAV vectors for CF therapy$388,750
R01 · FY2024 · HL · contact PI
Development of AAV vectors for CF therapy$388,750
R01 · FY2023 · HL · contact PI
Development of AAV vectors for CF therapy$388,750
R01 · FY2022 · HL · contact PI
Development of AAV vectors for CF therapy$388,750
R01 · FY2021 · HL · contact PI
Enhance AAV Liver Transduction with Capsid Immune Evasion$385,642
R01 · FY2020 · AI
Enhance AAV Liver Transduction with Capsid Immune Evasion$380,000
R01 · FY2019 · AI
Enhance AAV Liver Transduction with Capsid Immune Evasion$64,380
R01 · FY2019 · AI
Enhance AAV Liver Transduction with Capsid Immune Evasion$380,000
R01 · FY2018 · AI
NEUTRALIZING ANTIBODY & AAV FIX GENE THERAPY$2,278,426
P01 · FY2017 · HL · contact PI
Rational and Combinatorial Engineering of AAV Vectors$378,128
R01 · FY2017 · AI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2017 · AR
FIX GENE THERAPY AND ROLE OF AAV NAb$171,119
P01 · FY2017 · HL · contact PI
FIX GENE THERAPY AND ROLE OF AAV NAb$171,116
P01 · FY2017 · HL · contact PI
ADMINISTRATIVE CORE$63,713
P01 · FY2017 · HL · contact PI
ADMINISTRATIVE CORE$63,712
P01 · FY2017 · HL · contact PI
FIX GENE THERAPY AND ROLE OF AAV NAb$173,450
P01 · FY2016 · HL · contact PI
FIX GENE THERAPY AND ROLE OF AAV NAb$173,448
P01 · FY2016 · HL · contact PI
ADMINISTRATIVE CORE$64,600
P01 · FY2016 · HL · contact PI
ADMINISTRATIVE CORE$64,599
P01 · FY2016 · HL · contact PI
Neutralizing Antibody & AAV FIX Gene Therapy$2,272,304
P01 · FY2015 · HL · contact PI
Rational and Combinatorial Engineering of AAV Vectors$378,128
R01 · FY2015 · AI · contact PI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2015 · AR
AAV Gene Therapy for AAT Deficiency$319,241
R01 · FY2015 · DK · contact PI
FIX GENE THERAPY AND ROLE OF AAV NAb$171,400
P01 · FY2015 · HL · contact PI
FIX GENE THERAPY AND ROLE OF AAV NAb$171,398
P01 · FY2015 · HL · contact PI
ADMINISTRATIVE CORE$61,235
P01 · FY2015 · HL · contact PI
ADMINISTRATIVE CORE$61,232
P01 · FY2015 · HL · contact PI
Neutralizing Antibody & AAV FIX Gene Therapy$2,278,230
P01 · FY2014 · HL · contact PI
Rational and Combinatorial Engineering of AAV Vectors$378,128
R01 · FY2014 · AI · contact PI
CTL response to AAV Vector$363,116
R01 · FY2014 · AI · contact PI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2014 · AR · contact PI
AAV Gene Therapy for AAT Deficiency$319,241
R01 · FY2014 · DK · contact PI
Development of Human beta cell-specific AAV Vectors for Type I Diabetes$190,000
R21 · FY2014 · AI
FIX GENE THERAPY AND ROLE OF AAV NAb$175,365
P01 · FY2014 · HL · contact PI
FIX GENE THERAPY AND ROLE OF AAV NAb$175,361
P01 · FY2014 · HL · contact PI
ADMINISTRATIVE CORE$69,563
P01 · FY2014 · HL · contact PI
ADMINISTRATIVE CORE$69,559
P01 · FY2014 · HL · contact PI
Neutralizing Antibody & AAV FIX Gene Therapy$2,189,400
P01 · FY2013 · HL · contact PI
Rational and Combinatorial Engineering of AAV Vectors$355,440
R01 · FY2013 · AI · contact PI
FIX GENE THERAPY AND ROLE OF AAV NAb$352,005
P01 · FY2013 · HL · contact PI
CTL response to AAV Vector$341,329
R01 · FY2013 · AI · contact PI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2013 · AR · contact PI
AAV Gene Therapy for AAT Deficiency$308,068
R01 · FY2013 · DK · contact PI
Development of Human beta cell-specific AAV Vectors for Type I Diabetes$214,320
R21 · FY2013 · AI
ADMINISTRATIVE CORE$137,769
P01 · FY2013 · HL · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center$1,391,658
U54 · FY2012 · AR · contact PI
CTL response to AAV Vector$363,116
R01 · FY2012 · AI · contact PI
Rational and combinatorial engineering of AAV vectors$358,366
R01 · FY2012 · AI · contact PI
Adeno-associated Virus Vectors for Targeted and Repeat Delivery$330,067
U54 · FY2012 · AR · contact PI
AAV Gene Therapy for AAT Deficiency$319,241
R01 · FY2012 · DK · contact PI
American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting$10,000
R13 · FY2012 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center$1,398,548
U54 · FY2011 · AR · contact PI
CTL response to AAV Vector$363,116
R01 · FY2011 · AI · contact PI
Rational and combinatorial engineering of AAV vectors$358,458
R01 · FY2011 · AI · contact PI
Adeno-associated Virus Vectors for Targeted and Repeat Delivery$332,664
U54 · FY2011 · AR · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center$1,404,947
U54 · FY2010 · AR · contact PI
Differential regulation of multiple transgenes for treatment of eye disease$810,359
R01 · FY2010 · EY · contact PI
CTL response to AAV Vector$366,784
R01 · FY2010 · AI · contact PI
Rational and combinatorial engineering of AAV vectors$362,158
R01 · FY2010 · AI · contact PI
Adeno-associated Virus Vectors for Targeted and Repeat Delivery$335,185
U54 · FY2010 · AR · contact PI
AAV Gene Therapy for AAT deficiency$295,993
R01 · FY2010 · DK · contact PI
CTL response to AAV Vector$15,396
R01 · FY2010 · AI · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center$1,408,111
U54 · FY2009 · AR · contact PI
Differential regulation of multiple transgenes for treatment of eye disease$810,937
R01 · FY2009 · EY · contact PI
AAV BASED GENE THERAPY$408,038
P01 · FY2009 · GM · contact PI
Rational and combinatorial engineering of AAV vectors$365,587
R01 · FY2009 · AI · contact PI
Adeno-associated Virus Vectors for Targeted and Repeat Delivery$336,723
U54 · FY2009 · AR · contact PI
AAV Gene Therapy for AAT deficiency$296,000
R01 · FY2009 · DK · contact PI
CORE--VECTOR$99,301
P30 · FY2009 · CA · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center$52,295
U54 · FY2009 · AR · contact PI
Rational and combinatorial engineering of AAV vectors$7,212
R01 · FY2009 · AI · contact PI
Gene Therapy for Cystic Fibrosis$1,896,229
P01 · FY2008 · HL · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center$1,491,322
U54 · FY2008 · AR · contact PI
Parvovirus Vectors for Airway Delivery$418,462
P01 · FY2008 · HL · contact PI
AAV BASED GENE THERAPY$384,336
P01 · FY2008 · GM · contact PI
Rational and combinatorial engineering of AAV vectors$373,669
R01 · FY2008 · AI · contact PI
Adeno-associated Virus Vectors for Targeted and Repeat Delivery$337,966
U54 · FY2008 · AR · contact PI
Administrative Core$155,329
U54 · FY2008 · AR · contact PI
Muscle-specific AAV Vectors for DMD Gene Therapy$153,811
R21 · FY2008 · AR · contact PI
CORE--VECTOR$99,997
P30 · FY2008 · CA · contact PI
Gene Therapy for Cystic Fibrosis$1,881,961
P01 · FY2007 · HL · contact PI
Parvovirus Vectors for Airway Delivery$416,418
P01 · FY2007 · HL · contact PI
AAV BASED GENE THERAPY$395,763
P01 · FY2007 · GM · contact PI
Muscle-specific AAV Vectors for DMD Gene Therapy$188,340
R21 · FY2007 · AR · contact PI
CORE--VIRAL VECTOR AND GENOTYPING$141,827
P60 · FY2007 · AA · contact PI
CORE--VECTOR$95,860
P30 · FY2007 · CA · contact PI
Gene Therapy for Cystic Fibrosis$1,885,047
P01 · FY2006 · HL · contact PI
Parvovirus Vectors for Airway Delivery$290,135
P01 · FY2006 · HL · contact PI
AAV BASED GENE THERAPY$188,140
P01 · FY2006 · GM · contact PI
CORE--VIRAL VECTOR AND GENOTYPING$137,445
P60 · FY2006 · AA · contact PI
CORE--VECTOR$45,781
P30 · FY2006 · CA · contact PI
Gene Therapy for Cystic Fibrosis$1,877,073
P01 · FY2005 · HL
Gene Therapy Pulmonary &Hematologic Disorders$1,846,928
P01 · FY2005 · HL
Parvovirus Vectors for Airway Delivery$282,923
P01 · FY2005 · HL
AAV BASED GENE THERAPY$182,660
P01 · FY2005 · GM
rAAV Revitalized Structural Allografts$157,070
R43 · FY2005 · AR
CORE--VIRAL VECTOR AND GENOTYPING$137,445
P60 · FY2005 · AA
CORE--VECTOR$44,730
P30 · FY2005 · CA
Gene Therapy Pulmonary &Hematologic Disorders$1,852,206
P01 · FY2004 · HL
Gene Therapy for Cystic Fibrosis$1,834,646
P01 · FY2004 · HL
Parvovirus Vectors for Airway Delivery$275,000
P01 · FY2004 · HL
CORE--VIRAL VECTOR AND GENOTYPING$137,445
P60 · FY2004 · AA
Core A--Administrative Core$75,000
P01 · FY2004 · HL
Gene Therapy Pulmonary &Hematologic Disorders$1,857,226
P01 · FY2003 · HL
CORE--VIRAL VECTOR AND GENOTYPING$153,525
P60 · FY2003 · AA
Gene Therapy Pulmonary &Hematologic Disorders$1,860,492
P01 · FY2002 · HL
Resolving rate limiting steps for AAV vectors$265,784
P01 · FY2002 · HL
PARVOVIRUS VECTORS FOR AIRWAY EPITHELIAL CELLS$197,422
P01 · FY2002 · HL
CORE--VECTOR$197,422
P01 · FY2002 · HL
CORE--GENE DELIVERY$178,517
P50 · FY2002 · AA
NOVEL AAV-BASED VECTORS FOR GENE THERAPY$0
P01 · FY2002 · GM
CORE--GENE DELIVERY FACILITY$0
P01 · FY2002 · DK
Gene Therapy Pulmonary &Hematologic Disorders$1,862,400
P01 · FY2001 · HL
MUSCLE DELIVERY OF AAV VECTORS FOR GENE THERAPY$242,144
R01 · FY2001 · DK
PARVOVIRUS VECTORS FOR AIRWAY EPITHELIAL CELLS$197,422
P01 · FY2001 · HL
CORE--VECTOR$197,422
P01 · FY2001 · HL
CORE--GENE DELIVERY$178,517
P50 · FY2001 · AA
Resolving rate limiting steps for AAV vectors$0
P01 · FY2001 · HL
NOVEL AAV-BASED VECTORS FOR GENE THERAPY$0
P01 · FY2001 · GM
CORE--GENE DELIVERY FACILITY$0
P01 · FY2001 · DK
PARVOVIRUS VECTORS FOR AIRWAY EPITHELIAL CELLS$255,866
P01 · FY2000 · HL
CORE--VECTOR$255,866
P01 · FY2000 · HL
MUSCLE DELIVERY OF AAV VECTORS FOR GENE THERAPY$235,090
R01 · FY2000 · DK
RAAV TRANSDUCTION IN HUMAN HEMATOPOIETIC STEM CELL$226,918
R01 · FY2000 · HL
HYBRID PLASMID-AAV VECTORS FOR CFTR GENE THERAPY$197,019
R01 · FY2000 · DK
CORE--GENE DELIVERY$178,517
P50 · FY2000 · AA
CORE--VECTOR$0
P30 · FY2000 · CA
NOVEL AAV-BASED VECTORS FOR GENE THERAPY$0
P01 · FY2000 · GM